Alzheimer’s disease (AD) is a progressive neurodegenerative disease and symptoms develop gradually over many years. The current direction for medication development in AD is focused on neuro-inflammation and oxidative stress. Amyloid-β (Aβ) deposition activates microglia leading to neuro-inflammation and neurodegeneration induced by activation of COX-2 via NFκB p50 in glioblastoma cells.
Objective:
The study aimed to evaluate the concentration of COX-2 and NFκB p50 in serum of AD, mild cognitive impairment (MCI), and geriatric control (GC) and to establish a blood-based biomarker for early diagnosis and its therapeutic implications.
Methods:
Proteins and their mRNA level in blood of study groups were measured by surface plasmon resonance (SPR) and quantitative polymerase chain reaction (qPCR), respectively. The level of protein was further validated by western blot. The binding study of designed peptide against COX-2 by molecular docking was verified by SPR. The rescue of neurotoxicity by peptide was also checked by MTT assay on SH-SY5Y cells (neuroblastoma cell line).
Results:
Proteins and mRNA were highly expressed in AD and MCI compared to GC. However, COX-2 decreases with disease duration. The peptide showed binding affinity with COX-2 with low dissociation constant in SPR and rescued the neurotoxicity of SH-SY5Y cells by decreasing the level of Aβ, tau, and pTau proteins.
Conclusions:
It can be concluded that COX-2 protein can serve as a potential blood-based biomarker for early detection and can be a good platform for therapeutic intervention for AD.
GuanPP, WangP (2019) Integrated communications between cyclooxygenase-2 and Alzheimer’s disease. FASEB J33, 13–33.
2.
ArnaudL, RobakisNK, Figueiredo-PereiraME (2007) It may take inflammation, phosphorylation and ubiquitination to ‘tangle’ in Alzheimer’s disease. Neurodegener Dis3, 313–319.
3.
DuanY, ChenF, ZhangA, ZhuB, SunJ, XieQ, ChenZ (2014) Aspirin inhibits lipopolysaccharide-induced COX-2 expression and PGE2 production in porcine alveolar macrophages by modulating protein kinase C and protein tyrosine phosphatase activity. BMB Rep47, 45–50.
4.
LiuZ, LiT, LiP, WeiN, ZhaoZ, LiangH, JiX, ChenW, XueM, WeiJ (2015) The ambiguous relationship of oxidative stress, tau hyperphosphorylation, and autophagy dysfunction in Alzheimer’s disease. Oxid Med Cell Longev2015, 352723.
5.
RahmanA, AkterinS, Flores-MoralesA, CrisbyM, KivipeltoM, SchultzbergM, Cedazo-MínguezA (2005) High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice. FEBS Lett579, 6411–6416.
6.
KumarP, JhaNK, JhaSK, RamaniK, AmbastaRK (2015) Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: Clinical relevance in Alzheimer’s disease. J Alzheimers Dis43, 341–361.
7.
NaganoS, HuangX, MoirRD, PaytonSM, TanziRE, BushAI (2004) Peroxidase activity of cyclooxygenase-2 (COX-2) cross-links β-amyloid (Aβ) and generates Aβ-COX-2 hetero-oligomers that are increased in Alzheimer’s disease. J Biol Chem279, 14673–14678.
8.
TyagiA, KamalMA, PoddarNK (2020) Integrated pathways of COX-2 and mTOR: Roles in cell sensing and Alzheimer’s disease. Front Neurosci14, 693–706.
9.
BiringerRG (2019) The role of eicosanoids in Alzheimer’s disease. Int J Environ Res Public Health16, 2560–2592.
10.
LópezDE, BallazSJ (2020) The role of brain cyclooxygenase-2 (Cox-2) beyond neuroinflammation: Neuronal homeostasis in memory and anxiety. Mol Neurobiol57, 5167–5176.
11.
AmorS, PuentesF, BakerD, Van Der ValkP (2010) Inflammation in neurodegenerative diseases. Immunology129, 154–169.
12.
ShababT, KhanabdaliR, MoghadamtousiSZ, KadirHA, MohanG (2017) Neuroinflammation pathways: A general review. Int J Neurosci127, 624–633.
13.
LimGP, YangF, ChuT, ChenP, BeechW, TeterB, TranT, UbedaO, AsheKH, FrautschySA, ColeGM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci20, 5709–5714.
14.
KimJ, LeeHJ, ParkSK, ParkJH, JeongHR, LeeS, LeeH, SeolE, HoeHS (2021) Donepezil regulates LPS and Aβ-stimulated neuroinflammation through MAPK/NLRP3 inflammasome/STAT3 signaling. Int J Mol Sci22, 10637–10660.
15.
SomvanshiRK, KumarA, KantS, GuptaD, SinghSB, DasU, SrinivasanA, SinghTP, DeyS (2007) Surface plasmon resonance studies and biochemical evaluation of a potent peptide inhibitor against cyclooxygenase-2 as an anti-inflammatory agent. Biochem Biophys Res Commun361, 37–42.
16.
KapoorV, SinghAK, DeyS, SharmaSC, DasSN (2010) Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent. J Cancer Res Clin Oncol136, 1795–1804.
17.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
18.
DuboisB, FeldmanHH, JacovaC, DeKoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS–ADRDA criteria. Lancet Neurol6, 734–746.
19.
XueYW, ZhangQF, ZhuZB, WangQ, FuSB (2003) Expression of cyclooxygenase-2 and clinicopathologic features in human gastric adenocarcinoma. World J Gastroenterol9, 250–253.
20.
KordestaniZ, Shahrokhi-FarjahM, RouholaminiSE, SaberiA (2020) Reduced IKK/NF-kB expression by nigella sativa extract in breast cancer. Middle East J Cancer11,, 150–158.
21.
HuoC, ChenMH, HourTC, HuangLC, FongYO, KuoYY, YangYH, ChuuCP (2022) Application of micro-western array for identifying different serum protein expression profile among healthy control, Alzheimer’s disease patients and patients’ adult children. Brain Sci12, 1134.
22.
ParisD, PatelN, QuadrosA, LinanM, BakshiP, Ait-GhezalaG, MullanM (2007) Inhibition of Aβ production by NF-κB inhibitors. Neurosci Lett415, 11–16.
23.
RaoJS, KeleshianVL, KleinS, RapoportS (2012) Epigenetic modifications in frontal cortex from Alzheimer’s disease and bipolar disorder patients. Transl Psychiatry2, e132.
24.
PasinettiGM, AisenPS (1998) Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain. Neuroscience87, 319–324.
25.
OkaA, TakashimaS (1997) Induction of cyclo-oxygenase 2 in brains of patients with Down’s syndrome and dementia of Alzheimer type: Specific localization in affected neurones and axons. Neuroreport8, 1161–1164.
26.
RyuJK, McLarnonJG (2008) Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-α in an animal model of inflamed Alzheimer’s disease brain. Neurobiol Dis29, 254–266.
27.
CramerPE, CirritoJR, WessonDW, LeeCD, KarloJC, ZinnAE, CasaliBT, RestivoJL, GoebelWD, JamesMJ, BrundenKR (2012) ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science335, 1503–1506.
28.
MansourHM, FawzyHM, El-KhatibAS, KhattabMM (2021) Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates Alzheimer’s-like disease in D-galactose/ovariectomized rats. Neurochem Int150, 105178–105187.
ChoiHJ, JeongYJ, KimJ, HoeHS (2023) EGFR is a potential dual molecular target for cancer and Alzheimer’s disease. Front Pharmacol14,, 1238639–1238649.
31.
MoussaN, DayoubN (2023) Exploring the role of COX-2 in Alzheimer’s disease: Potential therapeutic implications of COX-2 inhibitors. Saudi Pharm J31, 101729.
